[b]Try right-hand column searching, and learn about what the mainstream media are hiding from us. Compare results from the BBC site with those of the Daily Sceptic site[/b]
@WalterF nothing to do with manufacturers as you'll know from working with pharmaceutical companies. Yellow cards are monitored by the authorities namely mhra and ukhsa in the uk
Vaccines are the best way to protect people from COVID-19 and have already saved tens of thousands of lives. Everyone should continue to get their vaccination when invited to do so unless specifically advised otherwise.
As with all vaccines and medicines, the safety of COVID-19 vaccines is being continuously monitored. The expected benefits of the vaccines in preventing COVID-19 and serious complications associated with COVID-19 far outweigh any currently known side effects in the majority of patients. Further information on the type of suspected adverse reactions (ADRs) reported for the COVID-19 Pfizer/BioNTech Vaccine, the COVID-19 Vaccine AstraZeneca and the COVID-19 Vaccine Moderna is provided in Annex 1. It is important to read the attached guidance notes to ensure appropriate interpretation of the data.[/quote]
@OldBrit I don't think I implied that companies have anything to do with yellow cards. They obviously don't. They have managed to free themselves from any responsibility for AEs. An extremely profitable situation for them. Never mind the fact that trials should be stopped when (or before) the number of vaccine deaths reaches double figures.
@WalterF but you monitor and unblind any reaction suspected death anyway and often will pause additional recruitment and dosing whilst they're investigated. I'm at a loss at what you'd do more. Obviously symptoms after 72hrs after injection would be excluded as that's after vaccine has been secreted. If you unblind all deaths you upset the value of having a rct anyway.
In my work career I challenged often on alternatives to rct especially where mortality is your measure to unblind and analyze but no one has come up with a better ethical solution yet.
Generally sponsors push for lower numbers believing the analysts will determine if a small sample whilst the regulators push for more to be safe but in a mortality study to see initial death expectations have to rise due to the regulators always erked me.
